Discover a new way to find and share stories you'll love… Learn about Reading Desk

Post Profile



Daiichi, Glaxo set up Japan venture

Japanese drugmaker Daiichi Sankyo and British peer GlaxoSmithKline are to form a 50-50 joint venture to bring new vaccines to Japan. ||| Japanese drugmaker Daiichi Sankyo and British peer GlaxoSmithKline are to form a 50-50 joint venture to bring new vaccines to Japan, targeting an underdeveloped segment of the world's second-biggest prescription drug market. News of the venture, which will likely create the top player in the Japanese vaccine market, sent shares of Japan's No.
read more

share
See more about: Daiichi Sankyo

A.M. Vitals: Daiichi Sankyo, GlaxoSmithKline Form Vaccine Venture

Health : Wall Street Journal Health Blog (3 years ago)

Also: CVS medication error; conflict over placenta; snoring and child behavior. Read Post

Daiichi Sankyo to buy Plexxikon | The Japan Times Online

Medical / Pharmaceutical : PharmaGossip (4 years ago)

Pharmaceutical giant Daiichi Sankyo Co. said Tuesday it has reached an agreement to wholly acquire Plexxikon Inc., a California-based drugmaker, for $805 million (about ¥66 billion) to strengthen its research and development of canc... Read Post

Daiichi Sankyo in friendly takeover of Ranbaxy

Medical / Pharmaceutical : PharmaGossip (6 years ago)

Daiichi Sankyo is buying control of India’s Ranbaxy Laboratories in a friendly takeover that could be worth as much as $4.6 billion.Under the terms of the deal, the Japanese drugmaker will acquire the 34.8% controlling stake of Ranb... Read Post


Copyright © 2011 Regator, LLC